Evidence map›Paper›PMID 39546036›Full record

Trial reportEuropean journal of nutrition2024

The effects of curcumin supplementation on inflammatory markers in systemic lupus erythematosus patients: a randomized placebo-controlled trial.

Sima Sedighi, Zeinab Faramarzipalangar, Elahe Mohammadi, Vahideh Aghamohammadi, Mehdi Gholami Bahnemiri, Kamran Mohammadi

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sima SedighiGolestan Rheumatology Research Center, Golestan University of Medical Science, Gorgan, Iran.
Zeinab FaramarzipalangarDepartment of Nutrition, School of Agricultural Sciences and Veterinary Medicine, University of Padua, Padua, Italy. zefaramarzyp78@yahoo.com.
Elahe MohammadiDepartment of Nutrition, Khalkhal University of Medical Sciences, Khalkhal, Iran. E.mohamadi52@yahoo.com.ORCID http://orcid.org/0000-0002-7148-1206
Vahideh AghamohammadiDepartment of Nutrition, Khalkhal University of Medical Sciences, Khalkhal, Iran.
Mehdi Gholami BahnemiriDepartment of Laboratory Sciences, Sari Branch, Islamic Azad University, Sari, Iran.
Kamran MohammadiDepartment of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Funding

Khalkhal University of Medical Sciences IR-KH-1399-10-019
6 · The paper itself

Abstract

purposeSystemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement. This study was designed to examine the effects of curcumin, a polyphenolic compound isolated from turmeric rhizomes, on inflammatory markers in SLE patients.

methodsSeventy 18-60 years old SLE patients were recruited in this randomized triple-blinded placebo-controlled trial, and 62 completed the study. Curcumin group received 1000 mg curcumin daily and the placebo group received placebo capsules for 10 weeks. Dietary intakes and serum levels of complement C3 and C4, complement hemolytic 50%, rheumatoid factor, anti-double stranded DNA (anti-ds DNA), erythrocyte sedimentation rate, high-sensitivity C-reactive protein, interlukine-6 (IL-6) and tumor necrosis factor-α were assessed before and after intervention period.

resultsCurcumin supplementation caused a significant reduction in anti-ds DNA and IL-6 levels at the end of the trial in comparison with baseline (52.57 ± 40.21 vs. 43.27 ± 28.34, p = 0.014 and 127.11 ± 76.63 vs. 101.49 ± 59.08, p = 0.002, respectively). Analysis of covariance which was adjusted for confounding variables also revealed that anti-ds DNA and IL-6 levels decreased significantly in curcumin group compared to placebo group by the end of the intervention period (change:-9.30 ± 19.59 vs. -2.55 ± 17.55, p = 0.018 and - 25.62 ± 42.33 vs. -7.34 ± 34.32, p = 0.043, respectively). No significant changes were observed in levels of other variables during the study (p > 0.05).

conclusionCurcumin as an effective and safe adjuvant therapy, ameliorated the autoimmune activity and inflammation in SLE patients via reducing anti-ds DNA and IL-6 levels. CLINICAL

trial registrationirct.behdasht.gov.ir, identifier: IRCT20210425051077N1.

Indexed as

BiomarkersC-Reactive ProteinCurcuminDietary SupplementsInterleukin-6Lupus Erythematosus, SystemicAdolescentAdultBlood SedimentationComplement C3Complement C4FemaleHumansInflammationMaleMiddle AgedBiomarkersComplement C3Complement C4C-Reactive ProteinCurcuminInterleukin-6Rheumatoid FactorTumor Necrosis Factor-alphaAutoimmunityCurcuminInflammationRandomized controlled trialSystemic lupus erythematosus

Identifiers

PMID39546036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.